Sign in Subscribe
Biochemistry

New Study on Non-Small Cell Lung Cancer Demonstrates Efficacy of Neoadjuvant Chemo-Immunotherapy and Antiangiogenic Drugs

Strategic Insights

— 1 min read

A recent study on non-small cell lung cancer (NSCLC) has shown promising results for a treatment regimen that combines neoadjuvant chemo-immunotherapy with antiangiogenic drugs. The study, conducted by researchers from the Department of Thoracic Surgery, found that this combination significantly improved long-term survival outcomes in patients with resectable NSCLC.

Key Takeaways:

  • The study evaluated the 3-year efficacy and safety of neoadjuvant sintilimab, anlotinib, and chemotherapy in 45 patients with resectable NSCLC from the TD-NeoFOUR trial.
  • The treatment regimen included neoadjuvant treatment with anlotinib, sintilimab, and platinum-based chemotherapy, followed by surgery.
  • The estimated 3-year event-free survival (EFS) rate was 84.3%, and the estimated 3-year overall survival (OS) rate was 86.7%.
  • Subgroup analysis showed that patients achieving pathological complete response (pCR) and major pathological response (MPR) had significantly higher 3-year EFS and OS rates compared to patients with non-pCR and non-MPR.
  • No new treatment-related adverse events (TRAEs) occurred during the 3-year follow-up, indicating the long-term safety of the treatment regimen.
  • The study concluded that the combination of neoadjuvant chemo-immunotherapy and antiangiogenic drugs is a promising option for improving prognosis in patients with resectable NSCLC.

Statistics:

  • 45 patients were included in the study.
  • The median follow-up time was 35.7 months.
  • The estimated 3-year EFS rate was 84.3%.
  • The estimated 3-year OS rate was 86.7%.
  • 100% of patients achieved disease control with the treatment regimen.

Sources:

  • Three-Year Follow-Up of the Phase II Trial for Resectable Non-Small-Cell Lung Cancer Treated With Perioperative Sintilimab and Neoadjuvant Anlotinib Plus Chemotherapy: TD-NeoFOUR Trial. Thoracic Cancer, 2025,16(16):n/a-n/a.
  • Our news editors report that additional information may be obtained by contacting Zhiyuan Gao, Department of Thoracic Surgery, Tangdu Hospital The Fourth Military Medical University Xi'an China.
  • Additional authors for this research include Yajie Mao, Yichen Sun, Liping Tong, Honggang Liu, Tianhu Wang, Changjian Shao, Hongtao Duan, Xiaolong Yan.

Read more